Immunocore : Corporate Presentation - January 2022

Corporate Presentation

40th Annual J.P. Morgan Healthcare Conference January 2022

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "believe," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this presentation include but are not limited to, statements about the Company's proposed regulatory plans for tebentafusp, the efficacy, safety and therapeutic potential of tebentafusp, the expected timing of a BLA review and action date for tebentafusp for the treatment of mUM, the potential approval and commercial launch of tebentafusp for mUM, the design, progress, timing, scope and results of the Company's clinical trials including IMC-C103C,IMC-F106C,IMC-I109V and IMC-M113V, the anticipated achievement of upcoming clinical milestones, the potential benefit of Breakthrough Therapy Designation or Orphan Drug Designation for tebentafusp the design, progress, timing, scope and results of the Company's clinical trials including IMC-C103C and tebentafusp; the potential clinical benefit of the Company's product candidates; the timing and outcome of discussions with regulatory authorities; and the success of any licensing or partnering opportunities. Each of these forward-looking statements involves risks and uncertainties. These statements are based on the Company's current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward- looking statements. Factors that may cause actual results to differ materially from these forward-looking statements include the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more clinical outcomes may materially change as patient enrollment continues and or more patient data becomes available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are discussed in Immunocore's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Immunocore's business and the overall global economy. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Except to the extent required by law, Immunocore undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Immunocore's own internal estimates and research. While Immunocore believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third - party sources.

2

© 2022 Immunocore. Not for further reproduction or distribution.

Harnessing the immune system to fight disease

with targeted, off-the-shelf, bispecific, soluble T cell receptors (TCRs)

Click to add text

T-cell receptor

T-cell receptor

ImmTAC

3

© 2022 Immunocore. Not for further reproduction or distribution.

Immunocore: Pioneering TCR therapeutics

Leader in off-the-shelf bispecific T-cell engagers

First TCR to demonstrate monotherapy overall survival (OS) benefit in solid tumor

Clinically-validated platform moving to commercialization in mUM1

Potential first FDA approval for a TCR therapeutic

Pipeline with potential in multiple indications / therapeutic areas

Oncology (tebentafusp, PRAME, MAGE-A4), infectious and autoimmune diseases 5 clinical stage programs

1. Metastatic uveal melanoma

4

© 2022 Immunocore. Not for further reproduction or distribution.

Our team

Proven track record with over 25 new medicines for patients

Bahija Jallal	Brian Di Donato
CEO	CFO & Head of Strategy

IMFINZI, FASENRA, LUMOXITI, SELIQ,

QAIV, SAPHNELO

Andy Hooker	JoAnn Suzich
VP, CMC & Supply Chain	Head of Research

CIMZIA	SYNAGIS, FLUMIST, VLP
	technology for HPV vaccines

David Berman	Mohammed Dar
Head of R&D	CMO

YERVOY, EMPLICITI, LUMOXITI, IMFINZI	VOTRIENT, IMFINZI, LUMOXITI

Mark Moyer	Ralph Torbay
Head of Regulatory	Head of Commercial

YERVOY, OPDIVO, TAXOTERE, ZOLADEX,	IMFINZI, TAGRISSO, CALQUENCE, GLEEVEC,
PLAVIX, JEVTANA, ELOXATIN	TASIGNA, ARZERRA, FARYDAK

5

© 2022 Immunocore. Not for further reproduction or distribution.